Technology Evaluation Consortium™ from One Million Solutions in Health™ to Validate a New Liver Toxicity Prediction Assay for Use in the Biopharmaceutical Industry

Share Article

A technology that can increase the accuracy of liver toxicity (hepatotoxicity) detection during the pre-clinical phase is currently undergoing evaluation by the Technology Evaluation Consortium™.

News Image
Hepatotoxicity is one of the most important reasons for the failure of drug candidates. This new technology has the potential to increase the accuracy of liver toxicity (hepatotoxicity) detection during the pre-clinical phase.

The Technology Evaluation ConsortiumTM, managed by One Million Solutions in Health™, has a TEC Validation Project™ underway to evaluate and validate a new liver toxicity prediction assay (hepatotoxicity) to further inform scientists in the drug discovery process. In particular, the Technology Evaluation Consortium is running blinded tests to demonstrate the performance of the new liver toxicity prediction assay technology.

Hepatotoxicity is one of the most important reasons for the failure of drug candidates during the clinical phase of drug development. Therefore, the Technology Evaluation Consortium will be evaluating a new liver toxicity prediction assay that increases the accuracy of hepatotoxicity detection during the PRE-clinical phase. The concept behind the assay is that a panel of hepatotoxicity biomarkers, validated to collectively detect hepatotoxicity, is more predictive than several biomarkers used individually.

This liver toxicity prediction assay has the unique potential to analyze different toxicities with multiple endpoints, considering factors such as metabolism and pharmacokinetics. The assay is particularly appropriate for safety assessment in the pre-clinical phase as it also provides valuable mechanistic information to support the data needed for regulatory submission of these pre-clinical experiments.

The Technology Evaluation Consortium (TEC) will bring together a number of industry leaders from pharmaceutical and biotech companies to accomplish the following goals in the TEC Validation Project for this liver toxicity prediction assay:

1.    Close collaboration with the TEC members to advance the technical and non-technical aspects of the in vivo liver toxicity prediction assay to achieve a strong, mutually agreed upon proof-of-concept (POC)

2.    Gain the interest of the TEC members in participating in a 2nd follow-on project, a Phase II TEC Validation Project aimed at closing any technical and non-technical gaps that will be identified by the TEC members during the execution of the present TEC Validation Project (Phase I)

3.    Optimize the new assay for adoption by the TEC members and by the pharmaceutical drug development industry in general

“We look forward to evaluating this new hepatotoxicity assay. Once validated, this assay could be immensely useful to our partners in the pharmaceutical industry,” explained Dawn Van Dam, President and CEO of One Million Solutions in Health.

Each member of the Technology Evaluation Consortium will nominate one Subject Matter Expert to represent their company. These experts will meet virtually once every two to three weeks to formulate the project and then to discuss updates about the project, offer advice, and decide the next steps. In this manner, the technology will be validated by the top minds in the field, from across the globe.


The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!


The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.

Dawn Van Dam
President and CEO

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dawn Van Dam
since: 04/2012
Follow >
One Million Solutions in Health
Like >
One Million Solutions in Health

Visit website